{"id":"bilastine","rwe":[{"pmid":"41891657","year":"2026","title":"Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution in Children and Adolescents: An 8-Week Phase 3 Study.","finding":"","journal":"Journal of investigational allergology & clinical immunology","studyType":"Clinical Study"},{"pmid":"41758678","year":"2026","title":"Effectiveness, Safety, and Tolerability of Bilastine Up-Dosing in Chronic Spontaneous Urticaria Uncontrolled with Licensed Doses of Other Second-Generation Antihistamines-An Institution-Based, Open-Label, Single-Group Longitudinal Trial.","finding":"","journal":"Indian dermatology online journal","studyType":"Clinical Study"},{"pmid":"41724883","year":"2026","title":"Risk of injury associated with the sedative potential of second-generation antihistamines: A nationwide retrospective cohort study.","finding":"","journal":"British journal of clinical pharmacology","studyType":"Clinical Study"},{"pmid":"41707943","year":"2026","title":"Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis.","finding":"","journal":"The journal of allergy and clinical immunology. In practice","studyType":"Clinical Study"},{"pmid":"41330702","year":"2025","title":"Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis.","finding":"","journal":"Allergy, asthma & immunology research","studyType":"Clinical Study"}],"tags":[{"label":"bilastine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"R06AX29","category":"atc"},{"label":"Active","category":"status"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Urticaria","category":"indication"}],"phase":"marketed","safety":{"safetySignals":[{"llr":490.946,"date":"","count":306,"signal":"Urticaria","source":"DrugCentral FAERS","actionTaken":"Reported 306 times (LLR=491)"},{"llr":200.859,"date":"","count":260,"signal":"Pruritus","source":"DrugCentral FAERS","actionTaken":"Reported 260 times (LLR=201)"},{"llr":155.604,"date":"","count":103,"signal":"Angioedema","source":"DrugCentral FAERS","actionTaken":"Reported 103 times (LLR=156)"},{"llr":114.866,"date":"","count":27,"signal":"Chronic spontaneous urticaria","source":"DrugCentral FAERS","actionTaken":"Reported 27 times (LLR=115)"},{"llr":100.071,"date":"","count":22,"signal":"Urticaria chronic","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=100)"},{"llr":85.62,"date":"","count":37,"signal":"Skin plaque","source":"DrugCentral FAERS","actionTaken":"Reported 37 times (LLR=86)"},{"llr":84.493,"date":"","count":102,"signal":"Inappropriate schedule of product administration","source":"DrugCentral FAERS","actionTaken":"Reported 102 times (LLR=84)"},{"llr":72.487,"date":"","count":91,"signal":"Asthma","source":"DrugCentral FAERS","actionTaken":"Reported 91 times (LLR=72)"},{"llr":68.966,"date":"","count":111,"signal":"Erythema","source":"DrugCentral FAERS","actionTaken":"Reported 111 times (LLR=69)"},{"llr":66.014,"date":"","count":14,"signal":"Urticaria thermal","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=66)"},{"llr":64.588,"date":"","count":6,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=65)"},{"llr":58.124,"date":"","count":51,"signal":"Illness","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=58)"},{"llr":56.974,"date":"","count":62,"signal":"Anaphylactic reaction","source":"DrugCentral FAERS","actionTaken":"Reported 62 times (LLR=57)"},{"llr":48.236,"date":"","count":13,"signal":"Mast cell activation syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=48)"},{"llr":47.405,"date":"","count":158,"signal":"Malaise","source":"DrugCentral FAERS","actionTaken":"Reported 158 times (LLR=47)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T15:44:28.403921","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BILASTINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:52:43.944584+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:52:49.326335+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BILASTINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:52:49.701805+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor inverse agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:50.747311+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1742423/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:50.405084+00:00"}},"allNames":"bellozal","offLabel":[],"synonyms":["bellozal","F-96221-BM1","bilastine","bilaxten"],"timeline":[],"brandName":"Bellozal","ecosystem":[{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Urticaria","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":68000000}],"mechanism":{"target":"Histamine H1 receptor","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor","isPrimary":true,"activityType":"Ki","activityValue":7.194}],"modality":"Small Molecule","drugClass":"bilastine","explanation":"","oneSentence":"","technicalDetail":"Bilastine is a selective, non-sedating H1 receptor antagonist that competes with histamine for binding to the H1 receptor, thereby inhibiting the histamine-mediated allergic response."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4353","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BILASTINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BILASTINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:00:08.702298","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:52.049399+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cyproheptadine","drugSlug":"cyproheptadine","fdaApproval":"1961-10-17","genericCount":31,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"antazoline","drugSlug":"antazoline","fdaApproval":"1990-04-30","relationship":"same-class"},{"drugName":"triprolidine","drugSlug":"triprolidine","fdaApproval":"1983-05-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azatadine","drugSlug":"azatadine","fdaApproval":"1977-03-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-class"},{"drugName":"terfenadine","drugSlug":"terfenadine","fdaApproval":"","relationship":"same-class"},{"drugName":"loratadine","drugSlug":"loratadine","fdaApproval":"1993-04-12","genericCount":29,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ketotifen","drugSlug":"ketotifen","fdaApproval":"1999-07-02","patentExpiry":"Mar 27, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"acrivastine","drugSlug":"acrivastine","fdaApproval":"1994-03-25","relationship":"same-class"},{"drugName":"azelastine","drugSlug":"azelastine","fdaApproval":"1996-11-01","patentExpiry":"Jun 4, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"epinastine","drugSlug":"epinastine","fdaApproval":"2003-10-16","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fexofenadine","drugSlug":"fexofenadine","fdaApproval":"1996-07-25","patentExpiry":"Aug 2, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"desloratadine","drugSlug":"desloratadine","fdaApproval":"2001-12-21","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"bilastine","indications":{"approved":[{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Urticaria","source":"DrugCentral","snomedId":126485001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"}],"offLabel":[],"pipeline":[]},"_fixedFields":["primaryTarget"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cyproheptadine","brandName":"cyproheptadine","genericName":"cyproheptadine","approvalYear":"1961","relationship":"same-class"},{"drugId":"antazoline","brandName":"antazoline","genericName":"antazoline","approvalYear":"1990","relationship":"same-class"},{"drugId":"triprolidine","brandName":"triprolidine","genericName":"triprolidine","approvalYear":"1983","relationship":"same-class"},{"drugId":"azatadine","brandName":"azatadine","genericName":"azatadine","approvalYear":"1977","relationship":"same-class"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-class"},{"drugId":"terfenadine","brandName":"terfenadine","genericName":"terfenadine","approvalYear":"","relationship":"same-class"},{"drugId":"loratadine","brandName":"loratadine","genericName":"loratadine","approvalYear":"1993","relationship":"same-class"},{"drugId":"ketotifen","brandName":"ketotifen","genericName":"ketotifen","approvalYear":"1999","relationship":"same-class"},{"drugId":"acrivastine","brandName":"acrivastine","genericName":"acrivastine","approvalYear":"1994","relationship":"same-class"},{"drugId":"azelastine","brandName":"azelastine","genericName":"azelastine","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07365683","phase":"NA","title":"Efficacy of Bilastine Up-dosing (40 mg ) Versus Combination of Bilastine (20 mg )With Levocitirizine (5 mg) in the Treatment of Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Derma Techno Pakistan","startDate":"2025-08-18","conditions":["Chronic Spontaneous Urticaria (CSU)"],"enrollment":60,"completionDate":"2026-01-17"},{"nctId":"NCT07042828","phase":"PHASE1","title":"To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2025-04-30","conditions":["Allergic Rhino-Conjunctivitis","Urticaria"],"enrollment":42,"completionDate":"2025-06-19"},{"nctId":"NCT06098261","phase":"PHASE1","title":"Bioequivalence Study of Bilastine Tablets in Healthy Chinese Subjects","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2023-11-21","conditions":["Healthy"],"enrollment":40,"completionDate":"2024-09-27"},{"nctId":"NCT04810390","phase":"PHASE3","title":"Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2021-03-26","conditions":["Allergic Conjunctivitis"],"enrollment":59,"completionDate":"2022-11-30"},{"nctId":"NCT03479307","phase":"PHASE3","title":"A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2018-04-07","conditions":["Allergic Conjunctivitis"],"enrollment":228,"completionDate":"2018-08-10"},{"nctId":"NCT03231969","phase":"PHASE2","title":"A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2017-07-20","conditions":["Allergic Conjunctivitis"],"enrollment":121,"completionDate":"2017-10-11"},{"nctId":"NCT04967092","phase":"PHASE2","title":"Modified Xiao-Feng Powder for Chronic Urticaria","status":"UNKNOWN","sponsor":"Prof. Lin Zhixiu","startDate":"2021-08-15","conditions":["Chronic Urticaria"],"enrollment":58,"completionDate":"2023-09-30"},{"nctId":"NCT02761252","phase":"PHASE4","title":"Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2016-04-13","conditions":["Seasonal Allergic Rhinoconjunctivitis","Asthma"],"enrollment":454,"completionDate":"2016-11-24"},{"nctId":"NCT00574379","phase":"PHASE2","title":"Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2007-12","conditions":["Seasonal Allergic Rhinitis","Hay Fever","Allergic Conjunctivitis","Hypersensitivity"],"enrollment":805,"completionDate":"2008-03"},{"nctId":"NCT00574210","phase":"PHASE2","title":"PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2007-10","conditions":["Seasonal Allergic Rhinitis","Hay Fever","Rhinoconjunctivitis"],"enrollment":502,"completionDate":"2008-02"},{"nctId":"NCT03633760","phase":"PHASE1","title":"Different Level of Single-dose and Multiple-dose Bilastine PK Study in Chinese Population","status":"UNKNOWN","sponsor":"A.Menarini Asia-Pacific Holdings Pte Ltd","startDate":"2018-08-28","conditions":["Pharmacokinetics"],"enrollment":24,"completionDate":"2019-07-31"},{"nctId":"NCT02513290","phase":"PHASE4","title":"Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine","status":"COMPLETED","sponsor":"Universidade do Sul de Santa Catarina","startDate":"2013-08","conditions":["Allergic Rhinitis"],"enrollment":73,"completionDate":"2014-08"},{"nctId":"NCT02576041","phase":"PHASE4","title":"Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria","status":"COMPLETED","sponsor":"Menarini International Operations Luxembourg SA","startDate":"2015-10","conditions":["Allergic Rhinitis","Urticaria"],"enrollment":19,"completionDate":"2015-12"},{"nctId":"NCT02213367","phase":"PHASE3","title":"Bilastine Updosing in Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-07","conditions":["Chronic Urticaria"],"enrollment":30,"completionDate":"2016-03"},{"nctId":"NCT02557269","phase":"PHASE4","title":"4\"S\" - Seasonal Symptoms Suppression Study","status":"UNKNOWN","sponsor":"Association Asthma, Bulgaria","startDate":"2015-05","conditions":["Seasonal Allergic Rhinitis"],"enrollment":60,"completionDate":"2015-12"},{"nctId":"NCT01400828","phase":"PHASE3","title":"Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2011-06","conditions":["Seasonal Allergic Rhinitis"],"enrollment":239,"completionDate":"2014-05"},{"nctId":"NCT01940393","phase":"PHASE4","title":"Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria","status":"COMPLETED","sponsor":"Grupo de Alergología Clínica y Experimental","startDate":"2013-08","conditions":["Urticaria"],"enrollment":150,"completionDate":"2014-01"},{"nctId":"NCT01127620","phase":"PHASE3","title":"Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2004-05","conditions":["Perennial Allergic Rhinitis"],"enrollment":650,"completionDate":"2006-11"},{"nctId":"NCT01081574","phase":"PHASE1,PHASE2","title":"Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2010-01","conditions":["Allergic Rhinoconjunctivitis","Chronic Urticaria"],"enrollment":36,"completionDate":"2012-06"},{"nctId":"NCT01124123","phase":"PHASE1","title":"Oral Bioavailability of Bilastine","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2010-05","conditions":["Healthy"],"enrollment":12,"completionDate":"2010-09"},{"nctId":"NCT00572611","phase":"PHASE1","title":"Human Mass Balance Study With Bilastine","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2007-11","conditions":["Healthy"],"enrollment":6,"completionDate":"2007-12"},{"nctId":"NCT01271075","phase":"PHASE2,PHASE3","title":"Bilastine Updosing - Characterization of Underlying Mechanisms","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2010-09","conditions":["Cold Contact Urticaria"],"enrollment":20,"completionDate":"2011-12"},{"nctId":"NCT01108783","phase":"PHASE3","title":"A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2003-04","conditions":["Seasonal Allergic Rhinitis"],"enrollment":720,"completionDate":"2004-02"},{"nctId":"NCT00420082","phase":"PHASE2","title":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2006-10","conditions":["Seasonal Allergic Rhinitis"],"enrollment":75,"completionDate":"2006-12"},{"nctId":"NCT00421109","phase":"PHASE3","title":"Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2006-07","conditions":["Urticaria"],"enrollment":522,"completionDate":"2007-07"},{"nctId":"NCT00419783","phase":"PHASE1","title":"A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2006-08","conditions":["Healthy"],"enrollment":30,"completionDate":"2006-12"},{"nctId":"NCT00504933","phase":"PHASE3","title":"Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2005-05","conditions":["Seasonal Allergic Rhinitis"],"enrollment":683,"completionDate":"2005-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"013709","UNII":"PA1123N395","CHEBI":"CHEBI:135954","INN_ID":"7905","UMLSCUI":"C1101148","chemblId":"CHEMBL1742423","ChEMBL_ID":"CHEMBL1742423","KEGG_DRUG":"D09570","DRUGBANK_ID":"DB11591","PUBCHEM_CID":"185460","SNOMEDCT_US":"697973006","IUPHAR_LIGAND_ID":"11579","MESH_SUPPLEMENTAL_RECORD_UI":"C445659"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.16 hours","clearance":"2.87 mL/min/kg","bioavailability":"61%","fractionUnbound":"0.13%","volumeOfDistribution":"0.61 L/kg"},"publicationCount":192,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"R06AX29","allCodes":["R06AX29","S01GX13"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 27","pmid":"41891657","title":"Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution in Children and Adolescents: An 8-Week Phase 3 Study.","journal":"Journal of investigational allergology & clinical immunology"},{"date":"2026 Mar 1","pmid":"41758678","title":"Effectiveness, Safety, and Tolerability of Bilastine Up-Dosing in Chronic Spontaneous Urticaria Uncontrolled with Licensed Doses of Other Second-Generation Antihistamines-An Institution-Based, Open-Label, Single-Group Longitudinal Trial.","journal":"Indian dermatology online journal"},{"date":"2026 Feb 22","pmid":"41724883","title":"Risk of injury associated with the sedative potential of second-generation antihistamines: A nationwide retrospective cohort study.","journal":"British journal of clinical pharmacology"},{"date":"2026 Feb 16","pmid":"41707943","title":"Efficacy and Safety of Oral Antihistamines for Allergic Rhinitis: Network Meta-Analysis.","journal":"The journal of allergy and clinical immunology. In practice"},{"date":"2025 Nov","pmid":"41330702","title":"Efficacy of a Combination Therapy of Montelukast and Antihistamines in Allergic Rhinitis: A Systematic Review and Network Meta-Analysis.","journal":"Allergy, asthma & immunology research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:52.049399+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}